BridgeBio Oncology Therapeutics, Inc. — All Filings
135 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
3
4
424B3
424B4
425
8-A12B
8-K
CERT
CORRESP
DRS
DRS/A
DRSLTR
EFFECT
POS AM
S-1
S-1/A
S-1MEF
S-4
S-4/A
S-8
SC 13D
SC 13G
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | 4 | 0001193125-26-126602 | Mar 26, 2026 | Mar 24, 2026 |
| 3 | 3 | 0001193125-26-126590 | Mar 26, 2026 | Mar 24, 2026 |
| 424B3 | 424B3 | 0001193125-26-126508 | Mar 26, 2026 | — |
| 8-K | 8-K | 0001193125-26-126493 | Mar 26, 2026 | Mar 24, 2026 |
| 4 | 4 | 0001193125-26-104384 | Mar 12, 2026 | Mar 10, 2026 |
| 4 | 4 | 0001193125-26-104379 | Mar 12, 2026 | Mar 10, 2026 |
| 4 | 4 | 0001193125-26-104369 | Mar 12, 2026 | Mar 10, 2026 |
| 424B3 | 424B3 | 0001193125-26-094856 | Mar 6, 2026 | — |
| 10-K | 10-K | 0001193125-26-094112 | Mar 5, 2026 | Dec 31, 2025 |
| 8-K | 8-K | 0001193125-26-093997 | Mar 5, 2026 | — |
| 424B3 | 424B3 | 0001193125-26-005435 | Jan 7, 2026 | — |
| 424B3 | 424B3 | 0001193125-26-005428 | Jan 7, 2026 | — |
| 8-K | 8-K | 0001193125-26-005425 | Jan 7, 2026 | — |
| 4 | 4 | 0001193125-26-003027 | Jan 5, 2026 | Jan 1, 2026 |
| S-8 | S-8 | 0001193125-26-000904 | Jan 2, 2026 | — |
| 4 | 4 | 0001193125-25-317962 | Dec 12, 2025 | Dec 10, 2025 |
| SCHEDULE 13G/A | — | 0001104659-25-112512 | Nov 14, 2025 | — |
| SCHEDULE 13G/A | — | 0000902664-25-004881 | Nov 13, 2025 | — |
| 10-Q | 10-Q | 0001193125-25-277834 | Nov 12, 2025 | Sep 30, 2025 |
| 8-K | 8-K | 0001193125-25-277601 | Nov 12, 2025 | — |
| S-8 | S-8 | 0001193125-25-237057 | Oct 10, 2025 | — |
| 4 | 4 | 0001193125-25-231917 | Oct 6, 2025 | Oct 2, 2025 |
| EFFECT | — | 9999999995-25-002915 | Sep 10, 2025 | — |
| 424B3 | 424B3 | 0001193125-25-200153 | Sep 10, 2025 | — |
| CORRESP | — | 0001193125-25-198323 | Sep 8, 2025 | — |
| UPLOAD | — | 0000000000-25-009499 | Sep 3, 2025 | — |
| SCHEDULE 13G | — | 0002013681-25-000001 | Sep 3, 2025 | — |
| S-1 | S-1 | 0001193125-25-192760 | Aug 29, 2025 | — |
| 4 | 4 | 0000950170-25-112020 | Aug 28, 2025 | Aug 26, 2025 |
| 4 | 4 | 0000950170-25-112016 | Aug 28, 2025 | Aug 26, 2025 |
| 4 | 4 | 0000950170-25-112008 | Aug 28, 2025 | Aug 26, 2025 |
| 4 | 4 | 0000950170-25-112003 | Aug 28, 2025 | Aug 26, 2025 |
| 4 | 4 | 0000950170-25-111997 | Aug 28, 2025 | Aug 26, 2025 |
| 4 | 4 | 0000950170-25-111992 | Aug 28, 2025 | Aug 26, 2025 |
| 4 | 4 | 0000950170-25-111986 | Aug 28, 2025 | Aug 26, 2025 |
| EFFECT | — | 9999999995-25-002673 | Aug 19, 2025 | — |
| SCHEDULE 13G | — | 0001193805-25-001205 | Aug 18, 2025 | — |
| SCHEDULE 13D | — | 0001193125-25-182790 | Aug 18, 2025 | — |
| 3 | 3 | 0000950170-25-109847 | Aug 18, 2025 | Aug 11, 2025 |
| 3 | 3 | 0000950170-25-109846 | Aug 18, 2025 | Aug 11, 2025 |
| 3 | 3 | 0000950170-25-109843 | Aug 18, 2025 | Aug 11, 2025 |
| 3 | 3 | 0000950170-25-109841 | Aug 18, 2025 | Aug 11, 2025 |
| 3 | 3 | 0000950170-25-109835 | Aug 18, 2025 | Aug 11, 2025 |
| 3 | 3 | 0000950170-25-109834 | Aug 18, 2025 | Aug 11, 2025 |
| 3 | 3 | 0000950170-25-109828 | Aug 18, 2025 | Aug 11, 2025 |
| 3 | 3 | 0000950170-25-109824 | Aug 18, 2025 | Aug 11, 2025 |
| 3 | 3 | 0000950170-25-109822 | Aug 18, 2025 | Aug 11, 2025 |
| POS AM | POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-4 | 0001213900-25-076945 | Aug 15, 2025 | — |
| SCHEDULE 13D/A | — | 0001213900-25-075307 | Aug 13, 2025 | — |
| 4 | — | 0001213900-25-075305 | Aug 13, 2025 | Aug 11, 2025 |